SCHEMBL2849488

SCHEMBL2849488

Cc1ccc(S(=O)(=O)OOC(C)C)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.46
CA2 P00918 3/20 0.43
CA1 P00915 2/20 0.43
CA12 O43570 2/20 0.43
CA9 Q16790 2/20 0.43
CA3 P07451 1/20 0.43
CA6 P23280 1/20 0.43
CA5A P35218 1/20 0.43
CA7 P43166 1/20 0.43
CA5B Q9Y2D0 1/20 0.43
VDR P11473 1/20 0.42
TLR9 Q9NR96 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
PTGS2 P35354 1/20 0.41
ALDH1A1 P00352 5/20 0.40
GBA1 P04062 1/20 0.40
MMP1 P03956 1/20 0.39
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39
MMP8 P22894 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7186972 0.83 GAA (0.59) GAACA2CA1CA12CA9
SCHEMBL30930716 0.82 HTR6 (0.41) CA2CA1CA12CA9CA3
SCHEMBL10402377 0.81 AGER (0.44) GAACA2CA1CA12CA9
SCHEMBL7758955 0.80 GAA (0.39) GAACA2CA1CA12CA9
SCHEMBL143705 0.79 GAA (0.50) GAACA2CA1CA12CA9
SCHEMBL476786 0.79 GAA (0.54) GAACA2CA1CA12CA9
Ammonia Solution, Strong SCHEMBL5917791 0.78 GAA (0.48) GAACA2CA1CA12CA9
SCHEMBL19949926 0.78 GAA (0.48) GAACA2CA1CA12CA9
SCHEMBL12846997 0.77 GAA (0.52) GAACA2CA1CA12CA9
SCHEMBL2342945 0.77 GAA (0.52) GAACA2CA1CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790725-B2 Thiazolidine derivatives and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-07 US disclosed
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2007-11-08 US disclosed
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-12-23 US disclosed
EP-1426366-A1 THIAZOLIDINE DERIVATIVE AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2004-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF DPP4, DPP7, DPP3 GAA 492/4885CA2 1210/4885CA1 3374/4885
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof DPP4, DPP7, DPP3 GAA 573/4885CA2 1129/4885CA1 2585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.